Radiopharm Theranostics (ASX:RAD) is raising up to $18.5 million via a two-tranche placement, a share purchase plan, and a concurrent US offering, aiming to bolster its clinical programs and working capital.
- Two-tranche placement to raise $6.7 million at $0.015 per share
- Share Purchase Plan offers up to 400 million shares with attaching options
- Concurrent US direct registration raises US$4.1 million with ADR warrants
- Equity raise proceeds to fund clinical trials, drug manufacturing, and working capital
- Offer subject to shareholder approval at September 2026 extraordinary general meeting
Capital Raise Targets $18.5 Million to Fuel Clinical Pipeline
Radiopharm Theranostics (ASX:RAD), a clinical-stage radiotherapeutics company focused on precision oncology, has launched a substantial equity raise aiming to secure up to AUD 18.5 million. The capital raising package comprises a two-tranche placement to sophisticated investors, a share purchase plan (SPP) for retail shareholders, and a concurrent US direct registration offering that raised approximately US$4.1 million (around AUD 5.8 million).
The placement offers up to 448.8 million new shares at an issue price of $0.015 each, representing a discount of over 21% to recent trading prices. Eligible shareholders can participate in the SPP to acquire up to 400 million shares at either $0.015 or a 2.5% discount to the five-day volume weighted average price (VWAP) before the SPP closes. Both the placement and SPP shares come with one free attaching option exercisable at $0.018 each, expiring on 31 July 2029, subject to shareholder approval.
Use of Funds and Financial Position
The funds raised will underpin Radiopharm’s ongoing clinical trial programs and drug manufacturing, with $3.7 million earmarked for manufacturing and $8.6 million for clinical trials. The remainder will support administration, working capital, and offer costs. The company’s pro forma cash balance post-raise is projected at approximately $51.6 million, providing a runway to advance its pipeline.
Radiopharm’s recent clinical progress includes positive Phase 2b results for its RAD101 imaging agent and promising early data for RAD204, underscoring the need for continued funding to support pivotal trials and regulatory activities. The company’s cash burn, previously reported at nearly $15 million per quarter, highlights the importance of this capital injection to sustain operations and development momentum.
Offer Details and Shareholder Impact
The placement is structured in two tranches: the first tranche of approximately 408.8 million shares will be issued in early August 2026, while the second tranche of 40 million shares is conditional on shareholder approval at an extraordinary general meeting (EGM) scheduled for 11 September 2026. The SPP will open on 7 August and close on 10 September, offering eligible shareholders the opportunity to participate up to $100,000 each.
In addition to the attaching options, Radiopharm is issuing 1,281,646 American Depositary Receipts (ADRs) warrants to US investors from the direct registration offering, exercisable at US$3.79 each. The company will also grant 64,082 agent warrants to the US placement agent, exercisable at US$3.95.
Shareholders should be mindful of dilution risks, as the raise will increase the total shares on issue by approximately 1.23 billion, diluting existing holdings proportionally. Directors have indicated their intention to participate in the SPP subject to shareholder approval, signalling confidence in the raise and the company’s prospects.
Risks and Regulatory Considerations
Radiopharm’s prospectus outlines a range of risks typical for a clinical-stage biotech, including the uncertainty of clinical trial outcomes, regulatory approvals, competitive pressures, and the need for future capital. The company currently generates no material revenue and depends heavily on successful trial progression and commercialisation of its novel radiopharmaceuticals.
The offer is not underwritten and is subject to shareholder approval, particularly for the second tranche of the placement, the SPP shares, attaching options, and warrants. Failure to secure approval would limit the raise to the first tranche of the placement only.
The company has taken care to comply with international securities laws, restricting offers to investors in jurisdictions where the offer is lawful, including Australia, New Zealand, and select institutional investors in the US, UK, Hong Kong, and Singapore.
Management and Governance
Radiopharm is led by Executive Chairman Paul Hopper, a biotech veteran with experience founding and leading multiple ASX-listed companies, and Managing Director Riccardo Canevari, who brings deep expertise in radiopharmaceutical commercialisation from his tenure at Novartis. The board includes experienced directors with backgrounds in nuclear medicine, pharmaceuticals, and finance, positioning the company to navigate the complex clinical and regulatory landscape ahead.
The company’s governance framework and constitution provide for shareholder rights, director remuneration, and protections against takeover bids, ensuring alignment with market standards.
Bottom Line?
Radiopharm’s $18.5 million capital raise is a critical step to fund its clinical ambitions, but shareholder approval and subscription levels will be decisive in shaping the company’s near-term trajectory.
Questions in the middle?
- Will shareholder approval be secured for the second tranche and attaching options at the September EGM?
- How will the company manage dilution pressures amid ongoing capital needs?
- What are the timelines and milestones for key clinical trials that the raise aims to support?